Medscape (6/25, Davenport, Subscription Publication) reports, “Patients with schizophrenia appear to prefer long-acting injectable (LAI) antipsychotics compared with oral versions of these medications primarily because injectables are more convenient and give individuals more control over their lives,” researchers concluded after analyzing “data on 1429 patients with schizophrenia who were participants in a double-blind, randomized, noninferiority study of paliperidone palmitate taken monthly vs once every three months.” The study also revealed that patients “prefer injections once every three months to monthly injections, citing the need for fewer” visits to physicians and less pain. The findings had been slated for presentation at the Congress of the Schizophrenia International Research Society 2020, but that meeting was canceled due to the COVID-19 pandemic.
Related Links:
— “Injectable vs Oral Antipsychotics: Which Do Patients Prefer?, “Liam Davenport, Medscape, June 25, 2020